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Basophil activation test: food challenge 
in a test tube or specialist research tool?
Alexandra F. Santos1,2* and Gideon Lack1,2
Abstract 
Oral food challenge (OFC) is the gold-standard to diagnose food allergy; however, it is a labour and resource-intensive 
procedure with the risk of causing an acute allergic reaction, which is potentially severe. Therefore, OFC are reserved 
for cases where the clinical history and the results of skin prick test and/or specific IgE do not confirm or exclude 
the diagnosis of food allergy. This is a significant proportion of patients seen in Allergy clinics and results in a high 
demand for OFC. The basophil activation test (BAT) has emerged as a new diagnostic test for food allergy. With high 
diagnostic accuracy, it can be particularly helpful in the cases where skin prick test and specific IgE are equivocal and 
may allow reducing the need for OFC. BAT has high specificity, which confers a high degree of certainty in confirm-
ing the diagnosis of food allergy and allows deferring the performance of OFC in patients with a positive BAT. The 
diagnostic utility of BAT is allergen-specific and needs to be validated for different allergens and in specific patient 
populations. Standardisation of the laboratory methodology and of the data analyses would help to enable a wider 
clinical application of BAT.
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Background
The gold-standard for the diagnosis of food allergy is oral 
food challenge (OFC) [1]. However, OFC requires the 
ingestion of the suspected culprit food and can cause an 
acute allergic reaction, which is potentially severe [2]. For 
this reason, OFC need to be performed in a supervised 
environment with the facilities and expertise to treat aller-
gic reactions and anaphylaxis, should they occur. OFC 
can cause significant anxiety in patients, parents and even 
clinical staff, as it involves considerable risk. Thus, when-
ever possible, the diagnosis of food allergy is established 
by a recent convincing history of an IgE-mediated aller-
gic reaction to the culprit food combined with evidence of 
IgE sensitization to the same food by skin prick test (SPT) 
and/or serum specific IgE (sIgE) [3]. OFC are reserved for 
the cases where the results of SPT and/or sIgE are equivo-
cal. With increased awareness and increased prevalence 
of food allergy and food sensitization, more and more 
patients are being tested for food allergy. The absence 
of a history of oral exposure to allergenic foods, either 
resulting in an allergic reaction or in the absence of clini-
cal symptoms, can make the interpretation of the results 
of the SPT and sIgE particularly challenging. Infants and 
young children who have never had certain allergenic 
foods constitute a considerable proportion of patients 
seen in Allergy clinics and often need an OFC to clarify 
their allergic status. This results in increasing demand in 
the performance of OFC. Allergy services have difficulty 
in responding to this demand and patients may need to 
wait several months before being offered an exact diagno-
sis of food allergy or food tolerance by OFC, which can 
lead to unnecessary dietary restrictions and to significant 
anxiety associated with diagnostic uncertainty. OFC is 
also the gold-standard to assess resolution of food allergy, 
to determine the threshold dose and to monitor the clini-
cal response to immunomodulatory treatments for food 
allergy. In research studies, allergic patients often have to 
undergo repeated OFC to assess whether there has been 
any clinical improvement.
The BAT, being a functional assay, has the potential to 
resemble more closely the clinical phenotype of patients 
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than allergy tests that merely detect the presence of aller-
gen-specific IgE. In simple terms, the BAT can be seen as 
an OFC in a test tube, where instead of giving the food 
to a child by mouth, basophils involved in acute allergic 
reactions are exposed to a food extract in a test tube. 
Despite the analogy, differences between the two pro-
cedures and their clinical applications can be pointed 
out and here lays the question as to whether BAT can 
loyally mimic the gold standard OFC, i.e. whether BAT 
can reproduce in vitro the allergic reaction that happens 
in vivo during a positive OFC.
The basophil activation test
The BAT is a flow cytometry-based assay where the 
expression of activation markers is measured on the sur-
face of basophils following stimulation with allergen 
[4, 5]—Fig.  1. A positive basophil activation test can be 
seen as an in vitro surrogate of an acute allergic reaction 
in  vivo. In a study of patients allergic to hymenoptera 
venom, up-regulation of basophil activation markers was 
observed both in vitro following stimulation with yellow 
jacket or honey bee venom and ex vivo following a posi-
tive sting challenge [6]. In the same study, there was a 
general agreement between the clinical presentation (sys-
temic reaction versus large local reaction) and the results 
of BAT, suggesting that the BAT is a potential biomarker 
of anaphylaxis. Also in food allergic patients a good agree-
ment was found between the results of BAT and the 
outcome of OFC. In patients allergic to alpha-gal with 
delayed immediate-type allergic reactions to red meat, 
the activation of basophils ex  vivo in blood collected at 
different time points coincided with the development of 
systemic allergic reactions in vivo during the OFC [7]. The 
results of this study reinforce the role of basophils in food-
induced IgE-mediated allergic reactions and anaphylaxis.
Different cell-surface markers can be used to identify 
basophils in whole blood, including IgE, CD123 (with 
HLA-DR), CCR3 or CRTH2 (with CD3) or CD203c [4].
In peripheral blood, IgE is detected on basophils, dendritic 
cells, eosinophils, monocytes, macrophages, B cells and 
platelets, thus it is not specific for basophils. CD123 is the 
low affinity (α) subunit of the IL-3 receptor. It is expressed in 
high levels on plasmacytoid dendritic cells and basophils and 
in low levels on monocytes, eosinophils, myeloid dendritic 
cells and subsets of haematologic progenitor cells. Additional 
staining with HLA-DR discriminates between HLA-DR-
negative basophils and HLA-DR-positive dendritic cells and 
monocytes. CCR3 is the receptor for C–C type chemokines 
(e.g. eotaxin, MCP and RANTES) and is highly expressed 
on basophils and eosinophils but also on Th1 and Th2 cells. 
CRTH2 is another marker that is expressed by basophils, 
eosinophils and T cells, and thus  like CCR3, requires a T 
cell marker, such as CD3, to distinguish basophils from T 
cells. CD203c is constitutively and specifically expressed on 
basophils and therefore can be used as a single identification 
marker or in combination with other markers.
Following stimulation with allergen, the expression of 
different proteins is up-regulated on the surface of baso-
phils [4], namely CD63 [8] and CD203c [9, 10]. CD63 is a 
lysosomal-associated membrane protein (LAMP), which 
is not expressed on the surface of resting basophils but 
only on the membrane of the granules inside the cells [8]. 
When the granules fuse with the plasmatic membrane 
of the basophils during degranulation, CD63 becomes 
expressed on the surface of basophils [10]. CD203c is 
an enzyme that cleaves phosphodiester and phospho-
sulphate bonds, hydrolytically removing 5′-nucleotides 
successively from the 3′-hydroxy-termini of oligonu-
cleotides. It is exclusively and constitutively expressed 
in low levels on the surface of basophils and mast cells 
and its expression increases with cell activation. Basophil 
activation markers seem to form two distinct groups of 
markers that are up-regulated concomitantly: one includ-
ing CD63, CD107a and CD107b and another including 
Fig. 1 Diagram of the laboratory procedure for the basophil 
activation test. Following stimulation of blood cells with allergen or 
controls, blood cells are stained with antibodies coupled to a fluoro-
chrome, which allow the identification of cells and the measurement 
of the expression of activation markers using a flow cytometer
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CD203c, CD13 and CD164 [11]. CD63 and CD203c are 
the most commonly used basophil activation markers.
The laboratory procedure of the BAT consists of three 
stages: cell stimulation, cell staining and flow cytome-
try—Fig. 1. Blood should be processed as soon as possi-
ble after blood collection, as basophils lose their viability 
and reactivity over time. However, studies have been per-
formed with samples stored at +4 °C up to 24 h [12]. A 
small volume of blood (c.a. 1–2  ml depending on the 
number of conditions) is required for BAT. Crude aller-
gen extracts or purified or recombinant allergens can be 
used for cell stimulation. Different allergen concentra-
tions should be used, as the sensitivity of the basophils to 
specific allergen stimulation varies among patients.
The results of BAT can be determined in terms of 
percentage of basophils expressing the defined activa-
tion marker or in terms of mean fluorescence intensity 
(MFI) by calculating the stimulation index, i.e. the ratio 
between the MFI of the selected condition and the MFI 
of the negative control. The former is usually used for 
CD63 as CD63 is not expressed in resting cells and its 
expression after activation is bimodal. The latter is usu-
ally used for CD203c which is already expressed in rest-
ing cells and its increase following allergen stimulation is 
unimodal—Fig. 2.
In allergic patients, allergen-induced basophil activa-
tion typically results in a bell-shaped dose–response 
curve, with increasing concentrations of the allergen 
(usually 5–6 log difference) leading to a progressive 
increase in the expression of the basophil activation 
markers until reaching a plateau—Fig. 3.
There is a large degree of variability in the basophil 
response to allergen between individuals. In order to 
express this heterogeneity and to compare basophil 
responses between different patients, various parameters 
can be determined based on the dose–response curve, 
such as CD-max and EC50 (50  % effective concentra-
tion) or CDsens. CD-max is the maximal activation and 
corresponds to the maximum proportion of activated 
basophils at any concentration of allergen [5]. EC50 is 
the effective dose at 50 % of the maximal activation, and 
can also be represented as CDsens. First described by 
Johansson [13], CDsens is the inverse of the half-maximal 
effective concentration, i.e. the concentration at which 
basophil activation is half of the maximum activation, 
times 100 and can be calculated using the formula: CDs-
ens =  1/EC50 ×  100. CDmax and CDsens are measures of 
basophil reactivity and of basophil sensitivity, respec-
tively. Basophil reactivity can be defined as the degree 
of basophil activation, i.e. the proportion of activated 
basophils, and can also be measured as the percentage of 
CD63-positive basophils at different allergen concentra-
tions or as the ratio of the percentage of CD63-positive 
after stimulation with allergen and with anti-IgE. Baso-
phil sensitivity refers to the concentration of allergen at 
which basophils become activated and can be expressed 
as a percentage of the maximal effective dose (e.g. EC5, 
EC10) apart from EC50 and CDsens, previously mentioned. 
Figure  3 represents the basophil response of two dif-
ferent individuals, one with higher basophil reactivity 
and sensitivity (blue) and the other with lower basophil 
reactivity and sensitivity (red), i.e. with a smaller pro-
portion of basophils becoming activated  in response  to 
higher concentrations of the allergen. Shreffler and Patil 
[14] have proposed a novel parameter to measure baso-
phil responses, the area under the dose–response curve, 
which has the advantage of combining basophil reactivity 
and basophil sensitivity.
Using the basophil activation test to diagnose food 
allergies
In a recently published study [15], we assessed the utility 
of the BAT to diagnose peanut allergy in a well-charac-
terized population of peanut allergic, peanut sensitized 
and non-sensitized children. BAT showed high accu-
racy (97  %) in diagnosing peanut allergy and allowed a 
reduction in the number of OFC required by 66  %. We 
validated the diagnostic cut-offs in a prospectively and 
independently recruited population and the diagnostic 
performance of BAT was still very good in this second 
study population. Over the past few years, other studies 
have assessed the performance of BAT in the diagnosis of 
allergy to different foods, including peanut [12, 15–18], 
cow’s milk [19, 20], egg [17, 19], wheat [21–25], hazelnut 
[26–28], shellfish [29] and peach [30–32], as well as in the 
diagnosis of pollen-food syndromes [33–35]—Table  1. 
Case reports and small case series have suggested that 
BAT may also be useful to diagnose allergy to sesame [36] 
and to less common elicitors of IgE-mediated food aller-
gic reactions, such as rice [37] and short chain galacto-
oligosaccharides present in prebiotics [38]. A recently 
published position paper from the European Academy 
of Allergy and Clinical Immunology reviews the clinical 
applications of the BAT [39].
Various factors may influence the diagnostic perfor-
mance and cut-off values of BAT in different studies, 
some related to the study population, some related to 
the study design, some related to the laboratory pro-
cedure and to the methodology adopted for data analy-
ses—Table 2. Existing studies are heterogeneous in most 
of these aspects, which limits their comparability and a 
wider application of the diagnostic cut-offs determined 
in specific studies. The criterion to diagnose each food 
allergy is allergen-specific and the diagnostic accuracy 
may not be the same for different allergens. Additionally, 
the cut-offs defined in one population are not necessarily 
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directly transferrable to another population from a differ-
ent geographical location assessed in a different Allergy 
centre. One limitation of BAT is the fact that a small 
proportion of patients tested have non-responder baso-
phils (i.e. basophils that respond to a non-IgE-mediated 
positive control but not to IgE-mediated stimulants) 
and therefore have an uninterpretable result for the 
test. Additional challenges in translating the BAT from 
a research method to a diagnostic test in the clinic are 
related to the standardisation of the assay and its repro-
ducibility and also to the cost-effectiveness of includ-
ing BAT in the diagnostic approach of patients with 
suspected food allergy. These aspects have not yet been 
established and require further research.
The methodology adopted to perform the laboratory 
procedure and to analyse the flow cytometry data can 
have a significant impact on the results obtained for the 
BAT and, consequently, in its diagnostic accuracy. For 
example, identifying basophils using an anti-IgE antibody 
can activate the cells and alter the results obtained with 
a different method to identify the basophils. The expres-
sion of certain basophil identification markers, such as 
CCR3 [42] and CD123 [43] can change following baso-
phil activation. In a recent study, we described that in 
Fig. 2 Dot plots and histograms showing the expression of CD63 and CD203c on the surface of basophils in different conditions. Unstimulated cells 
(negative control) and cells stimulated with peanut or with anti-IgE (positive control) are represented. The expression of CD63 is measured as the 
percentage of positive basophils (left panel) and the expression of CD203c is measured as the stimulation index (SI), i.e. the ratio of the mean fluores-
cence intensity of stimulated cells and the negative control (right panel)
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about a quarter of patients, the expression of CD123, as 
detected by flow cytometry, can be reduced following 
basophil activation and therefore lead to a significant 
loss-to-analyses of activated cells using methods that rely 
on this marker to identify basophils. This could result in 
an increased number of misdiagnosis, particularly false-
negatives, with important consequences for individual 
patients. Adding the basophil specific marker CD203c to 
the gating strategy retained the cell number and allowed 
to reduce the number of false-negatives (from 5 to 1 %). 
The modified gating strategy improved both the sensitiv-
ity (from 88 to 98 %) and the specificity (from 94 to 96 %) 
of BAT, resulting in an overall enhancement of the accu-
racy of BAT to diagnose peanut allergy from 91 to 97 %—
Fig. 4. In order to conduct and interpret BAT successfully, 
“the devil is in the detail”; therefore, it is very important 
to carefully consider the methodological aspects of BAT.
Overall, as a diagnostic test, BAT has shown high 
specificity and positive predictive value. We validated 
the diagnostic cut-offs determined for peanut allergy in 
an independent prospectively recruited population [15] 
and the specificity and positive predictive value of BAT 
reached 100 %. The high specificity is an important addi-
tion to existing allergy tests, such as SPT and sIgE, which 
have high sensitivity but are not very specific. The high 
specificity implies that a positive BAT confirms the diag-
nosis of food allergy with confidence but a negative BAT 
does not necessarily exclude the diagnosis. Depending 
on the cost-benefit ratio and safety aspects, OFC can be 
done in patients where BAT provides an inconclusive 
result (namely patients with non-responder basophils) 
or in patients where BAT provides an inconclusive result 
and in patients where BAT was negative.
The approach to decide about the need for OFC fol-
lowing BAT also depends on how the result of BAT is 
considered in the context of the results of other allergy 
tests, either in combination, when all the results availa-
ble are considered simultaneously, or sequentially, where 
BAT is performed only in patients who had equivocal or 
discordant results for the other allergy tests. In our pre-
viously cited peanut study [15], we compared the per-
formance of BAT with that of other allergy tests done 
in parallel. BAT performed better than SPT, specific IgE 
to peanut and specific IgE to Ara h 2 and other peanut 
components. Considering single tests, the most accurate 
Fig. 3 Basophil reactivity and basophil sensitivity. Two examples of 
dose–response curves of basophil activation following stimulation 
with various concentrations of allergen from two different patients 
are represented. The proportion of CD63+ positive cells is a measure 
of basophil reactivity and EC50, the effective concentration at 50 % of 
the maximal activation, is a measure of basophil sensitivity
Table 1 Examples of study assessing the utility of BAT to diagnose food allergy
N number of study participants, PFS pollen-food syndrome, ND not determined, Vs versus, Sensit. sensitised but tolerant, NA non-sensitised non-allergic, SI stimulation 
index
Food Author year N Cut-offs Sensitivity Specificity
Peanut Santos 2014 [15] N = 104 ≥4.78 % CD63+ 97.6 % 96.0 %
Validation population N = 65 83.3 % 100 %
Glaumann 2012 [12] N = 38 ND 92 % 77 %
Javaloyes 2012 [16] N = 26 ND 92 % 95 %
Ocmant 2009 [17] N = 75 ≥9.1 % CD63+ 87 % 94 %
Hazelnut Brandström 2015 [28] N = 40 CD-sens > 1.7 100 % 97 %
Egg Ocmant 2009 [17] N = 67 ≥5 % CD63+ 77 % 100 %
Cow’s milk Sato 2010 [19] N = 50 SI CD203c ≥ 1.9 89 % 83 %
Wheat Tokuda 2009 [22] N = 58 ≥14.4 % CD203c+ 85 % 77 %
Apple (PFS) Ebo 2005 [34] N = 61 Vs sensit. ≥17 % CD63+
Vs NA ≥10 %
Vs sensit. = 88 %
Vs NA = 100 %
Vs sensit. = 75 %
Vs NA = 100 %
Hazelnut (PFS) Erdmann 2003 [33] N = 30 ≥6.7 % CD63+ 85 % 80 %
Celery (PFS) ≥6.3 % CD63+ 85 % 80 %
Carrot (PFS) ≥8.9 % CD63+ 85 % 85 %
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diagnostic test was the BAT. In order to make the most of 
the information available, the results of BAT can be used 
in combination with the results of other tests [15, 17, 44, 
45]. However, generally, the more tests used, the higher 
the diagnostic uncertainty (and the higher the number of 
OFC) given that different tests can provide contradictory 
results [15]. Better than combining the results of allergy 
tests simultaneously may be to use BAT sequentially in 
the food allergy diagnostic work-up, in patients who had 
an inconclusive result for the other allergy tests [15]. 
This approach can be advantageous also from a feasibil-
ity point of view, considering the practicalities involved 
in the performance of BAT, namely the need for fresh 
blood and the resources and technical expertise required. 
It would not be practical or even necessary to perform 
BAT in all the patients being investigated for suspected 
food allergy. BAT can be reserved for selected cases, 
particularly cases where there is no history of oral expo-
sure to the food or the clinical history is unclear and the 
results of SPT and specific IgE are inconclusive [15]. BAT 
could be used as a second step in the diagnostic work-
up, following clinical history and SPT and/or sIgE, in dif-
ficult cases, before deciding whether an OFC is required 
[15]—Fig.  5. The diagnostic accuracy and the superi-
ority of BAT over skin prick test and specific IgE needs 
to be assessed with other allergens and in other clinical 
settings.
Apart from distinguishing food allergic and food toler-
ant patients, the results of BAT can provide additional 
information about the characteristics of food-induced 
reactions that may be helpful in the management of aller-
gic patients [46, 47]. Different parameters of the BAT 
have been shown to reflect different characteristics of the 
allergic reactions, with the proportion of activated baso-
phils (basophil reactivity) reflecting the severity of aller-
gic symptoms and the dose at which basophils react to 
allergen in vitro (basophil sensitivity) reflecting the dose 
of food protein at which patients reacted during OFC 
[46]. These findings in peanut allergy have been repro-
duced in a subsequently published study [47] and may be 
applicable to other food allergies. In any case, the result 
of BAT should be taken in the context of other clini-
cal features and risk factors for severity, when assessing 
food-allergic patients.
Using the basophil activation test to monitor acquisition 
of tolerance to foods and the clinical response 
to immunomodulatory treatments for food allergy
Reflecting closely the clinical phenotype of allergic and 
tolerant patients, BAT can be useful in assessing the 
natural resolution of food allergies that are commonly 
outgrown over time, such as cow’s milk [44], egg [19] 
and wheat [45] allergies, and in determining when to re-
challenge the patients to assess whether the food can be 
reintroduced in the diet. BAT has shown to distinguish 
different phenotypes of patients with cow’s milk and egg 
allergies, namely patients that tolerate extensively heated 
forms of these foods while still reacting to the unheated 
Table 2 Examples of factors that can influence the diagnostic cut-offs for BAT in food allergy [4, 14, 39, 40, 41]
Study population Prevalence of the food allergy in the population
Origin of the study population (e.g. recruited from a specialized Allergy clinic or from the general population)
Geographical location
Associated respiratory and food allergies
Study design Inclusion criteria (e.g. whether sensitized as well as non-sensitized patients were included in the study)
Gold-standard used as a comparator to determine the diagnostic cut-offs
Criteria for performing OFC (e.g. whether patients with a history of anaphylaxis or other risk factors for a severe reaction 
or with high levels of IgE or large wheals on skin prick test were included)
OFC protocol (e.g. criteria for stopping the OFC, criteria for a positive OFC, intervals between doses and duration of 
OFC)
Laboratory procedure Interval between blood collection and the performance of BAT
Allergen extracts or purified/recombinant allergens used
Concentration of the allergens
Pre-incubation with IL-3
Markers and antibodies (e.g. clones, fluorochromes) used to identify the basophils and to detect basophil activation
Flow cytometry data analyses Adopted gating strategy
Parameters used as the outcomes of the test [e.g. CD63 or CD203c, % or SI, CD-sens, area under the dose–response 
curve]
Definition of negative gate
Whether results were corrected for the background
Cytometer used and application settings
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foods from patients who react to both extensively heated 
and unheated milk or egg [19, 48, 49].
BAT has also been used to monitor clinical response 
to immunomodulatory treatments for food allergy in 
research studies. Overall, in studies of immunotherapy 
to foods such as peanut [50–54], cow’s milk [55] and egg 
[56, 57], BAT has shown decreased basophil reactivity 
to the respective food allergens with treatment,  which 
is particularly evident at the lower concentrations of 
the allergen, reflecting the decrease in basophil sensi-
tivity. Interestingly, Thyagarajan et  al. [52] showed that, 
during peanut OIT, the reduction in basophil activation 
was not only happening in response to peanut but also 
to the bystander egg allergen (in egg allergic patients) 
and to anti-IgE but not to the non-IgE-mediated positive 
control, fMLP (formyl-methionyl-leucyl-phenylalanine), 
suggesting that the pathway downstream the IgE recep-
tor had become anergic. In a study of omalizumab in pea-
nut allergic patients [58], CD203c expression in the BAT 
decreased during treatment and returned to pre-treat-
ment levels after cessation of this therapy. Finally, the 
Chinese herbal medicine FAHF-2 [59] also showed a sig-
nificant inhibitory effect in basophil response in patients 
with allergy to different foods in parallel with clinical 
improvement.
Taken together, these studies illustrate that BAT can 
be repeated in the same patients over time to assess the 
changes in the immune response to food allergens with 
some sort of intervention, being it oral immunotherapy, 
sublingual immunotherapy, omalizumab, or other immu-
nomodulatory therapeutic or preventive strategies.
Future perspectives
With the view of applying BAT to the diagnosis of food 
allergy in clinical practice, further research is needed 
to define and validate diagnostic cut-offs for specific 
allergens and in different patient populations. Stand-
ardization of the laboratory procedures would be 
important to allow the comparability of the results of 
BAT between centers. This would require standardiza-
tion of the protocol for the in  vitro assay and of the 
flow cytometry and data analyses’ methods. The use of 
similar methodology for BAT would allow to compare 
the results of BAT in different centers, both for clini-
cal and for research purposes, including in multicenter 
studies.
Once appropriately validated for the diagnosis of spe-
cific food allergies, BAT can be used to monitor the clini-
cal response to immunomodulatory treatments such as 
allergen-specific immunotherapy and biologicals. BAT 
also has an enormous potential for mechanistic studies to 
improve our understanding of the role of basophils in the 
immune mechanisms of food allergy and food tolerance.
Conclusions
BAT is a valuable research tool and has shown promise 
as a clinically useful test. Recent studies have shown that 
BAT diagnoses food allergy with high accuracy and can 
be particularly useful in cases with unclear clinical his-
tory or equivocal results of other diagnostic tests, before 
deciding on whether oral food challenges are required. 
Fig. 4 Enhancement of the diagnostic accuracy of the basophil 
activation test to peanut using the basophil gating strategy SSClow/
CD203c+/CD123+/HLA-DR- (in red) compared to using SSClow/
CD123+/HLA-DR- (in blue). ROC curves of the average  % CD63+ 
basophils at 10 and 100 ng/ml of peanut extract using the two differ-
ent gating strategies
Fig. 5 The basophil activation test can be useful in selected patients, in whom the combination of the clinical history and skin prick test (SPT) and/
or specific IgE is inconclusive, before referring for oral food challenge. A positive BAT confirms the diagnosis of food allergy and allows to defer the 
performance of OFC. An equivocal or a negative BAT should be followed by OFC to clarify the diagnosis
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BAT can also be used to monitor the clinical response to 
immunomodulatory treatments for food allergy. Further 
studies to define and validate diagnostic cut-offs values, 
to standardize the adopted methodology and to assess its 
cost-effectiveness are desirable in order to enable a wider 
use of BAT in clinical practice.
Abbreviations
BAT: basophil activation test; MFI: mean fluorescence intensity; OFC: oral food 
challenge; SI: stimulation index; sIgE: specific IgE; SPT: skin prick test.
Authors’ contributions
AFS wrote the first draft, GL critically reviewed it and both authors read and 
approved the final manuscript.
Author details
1 Department of Paediatric Allergy, Division of Asthma, Allergy and Lung 
Biology, King’s College London, London, UK. 2 MRC and Asthma UK Centre 
in Allergic Mechanisms of Asthma, London, UK. 
Competing interests
The authors declare that they have no competing interests.
Received: 3 November 2015   Accepted: 29 January 2016
References
 1. Boyce JA, Assa’ad A, Burks AW, Jones SM, Sampson HA, Wood RA, Plaut M, 
Cooper SF, Fenton MJ, Arshad SH, et al. Guidelines for the diagnosis and 
management of food allergy in the United States: report of the NIAID-
sponsored expert panel. J Allergy Clin Immunol. 2010;126(6 Suppl):S1–58.
 2. Perry TT, Matsui EC, Conover-Walker MK, Wood RA. Risk of oral food chal-
lenges. J Allergy Clin Immunol. 2004;114(5):1164–8.
 3. Du Toit G, Santos A, Roberts G, Fox AT, Smith P, Lack G. The diagnosis 
of IgE-mediated food allergy in childhood. Pediatr Allergy Immunol. 
2009;20(4):309–19.
 4. Ebo DG, Bridts CH, Hagendorens MM, Aerts NE, De Clerck LS, Stevens WJ. 
Basophil activation test by flow cytometry: present and future applica-
tions in allergology. Cytometry B Clin Cytom. 2008;74(4):201–10.
 5. Kleine-Tebbe J, Erdmann S, Knol EF, MacGlashan DW Jr, Poulsen LK, Gibbs 
BF. Diagnostic tests based on human basophils: potentials, pitfalls and 
perspectives. Int Arch Allergy Immunol. 2006;141(1):79–90.
 6. Gober LM, Eckman JA, Sterba PM, Vasagar K, Schroeder JT, Golden DB, 
Saini SS. Expression of activation markers on basophils in a controlled 
model of anaphylaxis. J Allergy Clin Immunol. 2007;119(5):1181–8.
 7. Commins SP, James HR, Stevens W, Pochan SL, Land MH, King C, Moz-
zicato S, Platts-Mills TA. Delayed clinical and ex vivo response to mamma-
lian meat in patients with IgE to galactose-alpha-1,3-galactose. J Allergy 
Clin Immunol. 2014;134(1):108–15.
 8. Knol EF, Mul FP, Jansen H, Calafat J, Roos D. Monitoring human basophil 
activation via CD63 monoclonal antibody 435. J Allergy Clin Immunol. 
1991;88(3 Pt 1):328–38.
 9. Hauswirth AW, Natter S, Ghannadan M, Majlesi Y, Schernthaner GH, Sperr 
WR, Buhring HJ, Valenta R, Valent P. Recombinant allergens promote 
expression of CD203c on basophils in sensitized individuals. J Allergy Clin 
Immunol. 2002;110(1):102–9.
 10. Amano T, Furuno T, Hirashima N, Ohyama N, Nakanishi M. Dynamics of 
intracellular granules with CD63-GFP in rat basophilic leukemia cells. J 
Biochem. 2001;129(5):739–44.
 11. Hennersdorf F, Florian S, Jakob A, Baumgartner K, Sonneck K, Nordheim 
A, Biedermann T, Valent P, Buhring HJ. Identification of CD13, CD107a, 
and CD164 as novel basophil-activation markers and dissection of two 
response patterns in time kinetics of IgE-dependent upregulation. Cell 
Res. 2005;15(5):325–35.
 12. Glaumann S, Nopp A, Johansson SG, Rudengren M, Borres MP, Nilsson 
C. Basophil allergen threshold sensitivity, CD-sens, IgE-sensitization and 
DBPCFC in peanut-sensitized children. Allergy. 2012;67(2):242–7.
 13. Johansson SG, Nopp A, van Hage M, Olofsson N, Lundahl J, Wehlin L, 
Soderstrom L, Stiller V, Oman H. Passive IgE-sensitization by blood trans-
fusion. Allergy. 2005;60(9):1192–9.
 14. Patil SU, Shreffler WG. Immunology in the Clinic Review Series; focus on 
allergies: basophils as biomarkers for assessing immune modulation. Clin 
Exp Immunol. 2012;167(1):59–66.
 15. Santos AF, Douiri A, Becares N, Wu SY, Stephens A, Radulovic S, Chan SM, 
Fox AT, Du Toit G, Turcanu V, et al. Basophil activation test discriminates 
between allergy and tolerance in peanut-sensitized children. J Allergy 
Clin Immunol. 2014;134(3):645–52.
 16. Javaloyes G, Goikoetxea MJ, Garcia Nunez I, Sanz ML, Blanca M, Scheurer 
S, Vieths S, Ferrer M. Performance of different in vitro techniques in the 
molecular diagnosis of peanut allergy. J Investig Allergol Clin Immunol. 
2012;22(7):508–13.
 17. Ocmant A, Mulier S, Hanssens L, Goldman M, Casimir G, Mascart F, 
Schandene L. Basophil activation tests for the diagnosis of food allergy in 
children. Clin Exp Allergy. 2009;39(8):1234–45.
 18. Glaumann S, Nopp A, Johansson SG, Borres MP, Nilsson C. Oral peanut 
challenge identifies an allergy but the peanut allergen threshold sensitiv-
ity is not reproducible. PLoS One. 2013;8(1):e53465.
 19. Sato S, Tachimoto H, Shukuya A, Kurosaka N, Yanagida N, Utsunomiya T, 
Iguchi M, Komata T, Imai T, Tomikawa M, et al. Basophil activation marker 
CD203c is useful in the diagnosis of hen’s egg and cow’s milk allergies in 
children. Int Arch Allergy Immunol. 2010;152(Suppl 1):54–61.
 20. Ciepiela O, Zwiazek J, Zawadzka-Krajewska A, Kotula I, Kulus M, Demkow 
U. Basophil activation test based on the expression of CD203c in the 
diagnostics of cow milk allergy in children. Eur J Med Res. 2010;15(Suppl 
2):21–6.
 21. Carroccio A, Brusca I, Mansueto P, D’Alcamo A, Barrale M, Soresi M, Seidita 
A, La Chiusa SM, Iacono G, Sprini D. A comparison between two different 
in vitro basophil activation tests for gluten- and cow’s milk protein sensi-
tivity in irritable bowel syndrome (IBS)-like patients. Clin Chem Lab Med. 
2013;51(6):1257–63.
 22. Tokuda R, Nagao M, Hiraguchi Y, Hosoki K, Matsuda T, Kouno K, Morita E, 
Fujisawa T. Antigen-induced expression of CD203c on basophils predicts 
IgE-mediated wheat allergy. Allergol Int. 2009;58(2):193–9.
 23. Chinuki Y, Kaneko S, Dekio I, Takahashi H, Tokuda R, Nagao M, Fujisawa T, 
Morita E. CD203c expression-based basophil activation test for diagnosis 
of wheat-dependent exercise-induced anaphylaxis. J Allergy Clin Immu-
nol. 2012;129(5):1404–6.
 24. Carroccio A, Mansueto P, Iacono G, Soresi M, D’Alcamo A, Cavataio 
F, Brusca I, Florena AM, Ambrosiano G, Seidita A, et al. Non-celiac 
wheat sensitivity diagnosed by double-blind placebo-controlled 
challenge: exploring a new clinical entity. Am J Gastroenterol. 
2012;107(12):1898–906.
 25. Carroccio A, Brusca I, Mansueto P, Pirrone G, Barrale M, Di Prima L, Ambro-
siano G, Iacono G, Lospalluti ML, La Chiusa SM, et al. A cytologic assay 
for diagnosis of food hypersensitivity in patients with irritable bowel 
syndrome. Clin Gastroenterol Hepatol. 2010;8(3):254–60.
 26. Cucu T, De Meulenaer B, Bridts C, Devreese B, Ebo D. Impact of thermal 
processing and the Maillard reaction on the basophil activation of hazel-
nut allergic patients. Food Chem Toxicol. 2012;50(5):1722–8.
 27. Worm M, Hompes S, Fiedler EM, Illner AK, Zuberbier T, Vieths S. Impact 
of native, heat-processed and encapsulated hazelnuts on the allergic 
response in hazelnut-allergic patients. Clin Exp Allergy. 2009;39(1):159–66.
 28. Brandstrom J, Nopp A, Johansson SG, Lilja G, Sundqvist AC, Borres 
MP, Nilsson C. Basophil allergen threshold sensitivity and component 
resolved diagnostics improve hazelnut allergy diagnosis. Clin Exp Allergy. 
2015;45:1412.
 29. Ebo DG, Bridts CH, Hagendorens MM, De Clerck LS, Stevens WJ. Scampi 
allergy: from fancy name-giving to correct diagnosis. J Investig Allergol 
Clin Immunol. 2008;18(3):228–30.
 30. Gamboa PM, Sanz ML, Lombardero M, Barber D, Sanchez-Monje R, 
Goikoetxea MJ, Antepara I, Ferrer M, Salcedo G. Component-resolved 
in vitro diagnosis in peach-allergic patients. J Investig Allergol Clin Immu-
nol. 2009;19(1):13–20.
Page 9 of 9Santos and Lack  Clin Transl Allergy  (2016) 6:10 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 31. Gamboa PM, Caceres O, Antepara I, Sanchez-Monge R, Ahrazem O, Sal-
cedo G, Barber D, Lombardero M, Sanz ML. Two different profiles of peach 
allergy in the north of Spain. Allergy. 2007;62(4):408–14.
 32. Diaz-Perales A, Sanz ML, Garcia-Casado G, Sanchez-Monge R, Garcia-
Selles FJ, Lombardero M, Polo F, Gamboa PM, Barber D, Salcedo G. 
Recombinant Pru p 3 and natural Pru p 3, a major peach allergen, show 
equivalent immunologic reactivity: a new tool for the diagnosis of fruit 
allergy. J Allergy Clin Immunol. 2003;111(3):628–33.
 33. Erdmann SM, Heussen N, Moll-Slodowy S, Merk HF, Sachs B. CD63 expres-
sion on basophils as a tool for the diagnosis of pollen-associated food 
allergy: sensitivity and specificity. Clin Exp Allergy. 2003;33(5):607–14.
 34. Ebo DG, Hagendorens MM, Bridts CH, Schuerwegh AJ, De Clerck LS, 
Stevens WJ. Flow cytometric analysis of in vitro activated basophils, spe-
cific IgE and skin tests in the diagnosis of pollen-associated food allergy. 
Cytometry B Clin Cytom. 2005;64(1):28–33.
 35. Erdmann SM, Sachs B, Schmidt A, Merk HF, Scheiner O, Moll-Slodowy S, 
Sauer I, Kwiecien R, Maderegger B, Hoffmann-Sommergruber K. In vitro 
analysis of birch-pollen-associated food allergy by use of recombinant 
allergens in the basophil activation test. Int Arch Allergy Immunol. 
2005;136(3):230–8.
 36. Raap U, Wieczorek D, Schenck F, Kapp A, Wedi B. The basophil activation 
test is a helpful diagnostic tool in anaphylaxis to sesame with false-nega-
tive specific IgE and negative skin test. Allergy. 2011;66(11):1497–9.
 37. Trcka J, Schad SG, Scheurer S, Conti A, Vieths S, Gross G, Trautmann A. 
Rice-induced anaphylaxis: IgE-mediated allergy against a 56-kDa glyco-
protein. Int Arch Allergy Immunol. 2012;158(1):9–17.
 38. Chiang WC, Huang CH, Llanora GV, Gerez I, Goh SH, Shek LP, Nauta AJ, Van 
Doorn WA, Bindels J, Ulfman LH, et al. Anaphylaxis to cow’s milk formula 
containing short-chain galacto-oligosaccharide. J Allergy Clin Immunol. 
2012;130(6):1361–7.
 39. Hoffmann HJ, Santos AF, Mayorga C, Nopp A, Eberlein B, Ferrer M, 
Rouzaire P, Ebo DG, Sabato V, Sanz ML, et al. The clinical utility of basophil 
activation testing in diagnosis and monitoring of allergic disease. Allergy. 
2015;70(11):1393–405.
 40. Santos AF, Du Toit G, Lack G. Is the use of epinephrine a good marker of 
severity of allergic reactions during oral food challenges? J Allergy Clin 
Immunol Pract. 2015;3(3):429–30.
 41. Chirumbolo S, Vella A, Ortolani R, De Gironcoli M, Solero P, Tridente G, 
Bellavite P. Differential response of human basophil activation markers: a 
multi-parameter flow cytometry approach. Clin Mol Allergy. 2008;6:12.
 42. Hausmann OV, Gentinetta T, Fux M, Ducrest S, Pichler WJ, Dahinden CA. 
Robust expression of CCR3 as a single basophil selection marker in flow 
cytometry. Allergy. 2011;66(1):85–91.
 43. Santos AF, Becares N, Stephens A, Turcanu V, Lack G: The expression 
of CD123 can decrease with basophil activation – implications for the 
gating strategy of the basophil activation test. Clinical and Translational 
Allergy. 2016. doi:10.1186/s13601-016-0100-4.
 44. Rubio A, Vivinus-Nebot M, Bourrier T, Saggio B, Albertini M, Bernard A. 
Benefit of the basophil activation test in deciding when to reintroduce 
cow’s milk in allergic children. Allergy. 2011;66(1):92–100.
 45. Nilsson N, Nilsson C, Hedlin G, Johansson SG, Borres MP, Nopp A. Combin-
ing Analyses of Basophil Allergen Threshold Sensitivity, CD-sens, and IgE 
Antibodies to Hydrolyzed Wheat, omega-5 Gliadin and Timothy Grass 
Enhances the Prediction of Wheat Challenge Outcome. Int Arch Allergy 
Immunol. 2013;162:50–7.
 46. Santos AF, Du Toit G, Douiri A, Radulovic S, Stephens A, Turcanu V, Lack 
G. Distinct parameters of the basophil activation test reflect the severity 
and threshold of allergic reactions to peanut. J Allergy Clin Immunol. 
2015;135(1):179–86.
 47. Song Y, Wang J, Leung N, Wang LX, Lisann L, Sicherer SH, Scurlock AM, 
Pesek R, Perry TT, Jones SM, et al. Correlations between basophil activa-
tion, allergen-specific IgE with outcome and severity of oral food chal-
lenges. Ann Allergy Asthma Immunol. 2015;114(4):319–26.
 48. Wanich N, Nowak-Wegrzyn A, Sampson HA, Shreffler WG. Allergen-spe-
cific basophil suppression associated with clinical tolerance in patients 
with milk allergy. J Allergy Clin Immunol. 2009;123(4):789–794 e720.
 49. Ford LS, Bloom KA, Nowak-Wegrzyn AH, Shreffler WG, Masilamani M, 
Sampson HA: Basophil reactivity, wheal size, and immunoglobulin levels 
distinguish degrees of cow’s milk tolerance. J Allergy Clin Immunol. 
2012([epub ahead of print]).
 50. Wood RA, Sicherer SH, Burks AW, Grishin A, Henning AK, Lindblad R, 
Stablein D, Sampson HA. A phase 1 study of heat/phenol-killed, E. 
coli-encapsulated, recombinant modified peanut proteins Ara h 1, Ara 
h 2, and Ara h 3 (EMP-123) for the treatment of peanut allergy. Allergy. 
2013;68(6):803–8.
 51. Fleischer DM, Burks AW, Vickery BP, Scurlock AM, Wood RA, Jones SM, 
Sicherer SH, Liu AH, Stablein D, Henning AK, et al. Sublingual immu-
notherapy for peanut allergy: a randomized, double-blind, placebo-
controlled multicenter trial. J Allergy Clin Immunol. 2013;131(1):119–127 
e111–7.
 52. Thyagarajan A, Jones SM, Calatroni A, Pons L, Kulis M, Woo CS, Kamala-
kannan M, Vickery BP, Scurlock AM, Wesley Burks A. Evidence of pathway-
specific basophil anergy induced by peanut oral immunotherapy in 
peanut-allergic children. Clin Exp Allergy. 2012;42(8):1197–205.
 53. Kim EH, Bird JA, Kulis M, Laubach S, Pons L, Shreffler W, Steele P, Kamilaris 
J, Vickery B, Burks AW. Sublingual immunotherapy for peanut allergy: 
clinical and immunologic evidence of desensitization. J Allergy Clin 
Immunol. 2011;127(3):640–6, e641.
 54. Jones SM, Pons L, Roberts JL, Scurlock AM, Perry TT, Kulis M, Shreffler 
WG, Steele P, Henry KA, Adair M, et al. Clinical efficacy and immune 
regulation with peanut oral immunotherapy. J Allergy Clin Immunol. 
2009;124(2):292–300, 300 e291–7.
 55. Keet CA, Frischmeyer-Guerrerio PA, Thyagarajan A, Schroeder JT, Hamilton 
RG, Boden S, Steele P, Driggers S, Burks AW, Wood RA. The safety and 
efficacy of sublingual and oral immunotherapy for milk allergy. J Allergy 
Clin Immunol. 2012;129(2):448–455, 455 e441-–5.
 56. Burks AW, Jones SM, Wood RA, Fleischer DM, Sicherer SH, Lindblad RW, 
Stablein D, Henning AK, Vickery BP, Liu AH, et al. Oral immunotherapy for 
treatment of egg allergy in children. N Engl J Med. 2012;367(3):233–43.
 57. Vila L, Moreno A, Gamboa PM, Martinez-Aranguren R, Sanz ML. Decrease 
in antigen-specific CD63 basophil expression is associated with the 
development of tolerance to egg by SOTI in children. Pediatr Allergy 
Immunol. 2013;24(5):463–8.
 58. Gernez Y, Tirouvanziam R, Yu G, Ghosn EE, Reshamwala N, Nguyen T, 
Tsai M, Galli SJ, Herzenberg LA, Nadeau KC. Basophil CD203c levels 
are increased at baseline and can be used to monitor omalizumab 
treatment in subjects with nut allergy. Int Arch Allergy Immunol. 
2011;154(4):318–27.
 59. Patil SP, Wang J, Song Y, Noone S, Yang N, Wallenstein S, Sampson HA, Li 
XM. Clinical safety of Food Allergy Herbal Formula-2 (FAHF-2) and inhibi-
tory effect on basophils from patients with food allergy: Extended phase I 
study. J Allergy Clin Immunol. 2011;128(6):1259–65, e1252.
